We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01055691
First Posted: January 26, 2010
Last Update Posted: June 1, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
AstraZeneca
  Purpose
The primary objective of the study is to establish if the same amount of drug is absorbed into the blood after ingesting a combination dapagliflozin/metformin tablet vs. the individual dapagliflozin tablet and individual metformin tablet.

Condition Intervention Phase
Healthy Volunteers Drug: Dapagliflozin/Metformin Drug: Dapagliflozin Drug: Metformin Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Two Part, Open Label, Randomized, Phase I Bioequivalence Study Comparing the Fixed Dose Combination Dapagliflozin/Metformin IR Tablet (2.5 mg/850 mg or 5 mg/1000 mg) vs. the Free Combination of Dapagliflozin and Metformin IR Tablets, in Healthy Volunteers, in the Fed State

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • bioequivalence will be demonstrated if the 90% confidence interval (CI) for the formulation effect is contained within the interval of 0.8000-1.2500 for AUC(0-t), AUCinf and Cmax with respect to both dapagliflozin and metformin. [ Time Frame: Immediately prior to administration of the investigational product (IP). After intake of IP PK blood samples will be drawn every 15 minutes for the first hour, every 30 minutes for the second hour and every hour up to 72 h after intake of IP. ]

Secondary Outcome Measures:
  • To examine the safety and tolerability of the combination of dapagliflozin and metformin. [ Time Frame: Throughout study (for 4 days in each period and a follow-up visit ~6 days later) ]

Enrollment: 120
Study Start Date: January 2010
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
Drug: Dapagliflozin/Metformin
Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose
Drug: Dapagliflozin
dapagliflozin tablet 2.5 mg Oral Single dose
Drug: Metformin
metformin IR tablet 850 mg Oral Single dose
Other Name: Glucophage
Experimental: 2
Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
Drug: Dapagliflozin/Metformin
Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose
Drug: Dapagliflozin
dapagliflozin tablet 2.5 mg Oral Single dose
Drug: Metformin
metformin IR tablet 850 mg Oral Single dose
Other Name: Glucophage
Experimental: 3
Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
Drug: Dapagliflozin/Metformin
Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose
Drug: Dapagliflozin
dapagliflozin tablet 5 mg Oral Single dose
Drug: Metformin
metformin IR tablet 1000 mg Oral Single dose
Other Name: Glucophage
Experimental: 4
Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
Drug: Dapagliflozin/Metformin
Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose
Drug: Dapagliflozin
dapagliflozin tablet 5 mg Oral Single dose
Drug: Metformin
metformin IR tablet 1000 mg Oral Single dose
Other Name: Glucophage

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female healthy volunteers must be post-menopausal (cessation of menses >1year), be surgically sterile (documented) or hysterectomy or on abstinence
  • Have normal physical exam, vital signs Electrocardiogram (ECG) findings, and laboratory values

Exclusion Criteria:

  • Use of prescription medication for a chronic or acute medical condition within 3 weeks of randomization
  • History of allergy to metformin
  • Previous participation in an AstraZeneca (AZ) or BristolMyers-Sqibb dapagliflozin study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01055691


Locations
Germany
Research Site
Berlin, Germany
Sponsors and Collaborators
AstraZeneca
Bristol-Myers Squibb
Investigators
Principal Investigator: Georg Golor, M.D. Parexel
Study Director: Thomas Koernicke Parexel
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01055691     History of Changes
Other Study ID Numbers: D1691C00002
First Submitted: January 25, 2010
First Posted: January 26, 2010
Last Update Posted: June 1, 2012
Last Verified: May 2012

Keywords provided by AstraZeneca:
healthy volunteers
bioequivalence
dapagliflozin
metformin

Additional relevant MeSH terms:
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs